What this means
This study is a trial that is still enrolling people, so no results are available yet. It aims to check whether a low dose is safe and works for older adults within 4.5 hours of a stroke.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 70 and over
- Where
- 51 sites
The science
- Registered title
- Low-Dose Tenecteplase for Acute Ischemic Stroke Treatment in Aging Patients
- Trial ID
- NCT07294209 ↗
- Phase
- PHASE 4
- Study type
- interventional
- Conditions
- Acute Ischemic Stroke Patients
- What is tested
- low-dose tenecteplase intravenous thrombolysis, standard-dose tenecteplase intravenous thrombolysis
- Sponsor
- Southwest Hospital, China
- Ages
- 70 Years to no maximum
- Dates
- First posted Dec 19, 2025 · updated Jun 23, 2026
Registry summary
The DATE-AGING study is a prospective, multicenter, randomized controlled trial investigating low-dose tenecteplase in elderly patients with acute ischemic stroke. Its primary objective is to evaluate the safety and efficacy of low-dose tenecteplase in elderly patients within 4.5 hours of acute ischemic stroke onset.
Sites (51)
- Southwest Hospital, Chongqing, China, Chongqing, Chongqing Municipality, China
- Wuchang People's Hospital, Harbin, Heilongjiang, China
- Shenqiu County People's Hospital, Zhoukou, Henan, China
- Anshan Changda Hospital, Anshan, China
- Anyang People's Hospital, Anyang, China
- Huaxian People's Hospital of Henan, Anyang, China
- Baoshan People's Hospital, Baoshan, China
- People's Hospital of Zhijin County, Bijie, China
- Bishan Hospital, Chongqing, China
- Chongqing Emergency Medical Center, Chongqing, China
- Chongqing University Fuling Hospital, Chongqing, China
- Chongqing University Jiangjin Hospital, Chongqing, China
- Chongqing University Three Gorges Hospital, Chongqing, China
- Dianjiang People's Hospital OF Chongqing, Chongqing, China
- People's Hospital Of Xiushan County, Chongqing, China
And 36 more on the listing.